{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:25:44Z","timestamp":1794885944413,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes. This review synthesizes current evidence on pharmacokinetics, safety in preconception and early pregnancy, and clinical management strategies for glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in women of reproductive age. Ethical and health system considerations are also explored to inform clinical practice and highlight future research priorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar identified 132 articles. After screening and full-text review, 9 studies met the inclusion criteria for synthesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Semaglutide (~7\u00a0days) and tirzepatide (~5\u00a0days) have long half-lives, requiring discontinuation at least 35\u00a0days and 25\u201335\u00a0days, respectively, before conception, while liraglutide requires \u22653\u00a0days. Human data show no significant increase in congenital anomalies with inadvertent early exposure, although evidence is limited and observational. Alternatives such as metformin, lifestyle modification, and bariatric surgery remain safer options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GLP-1 RAs may aid preconception metabolic optimization; however, evidence remains limited and largely observational. Preconception discontinuation timed to each agent\u2019s half-life is prudent to minimize potential fetal exposure. Prospective studies and pregnancy registries are needed to confirm reproductive safety and refine guidance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004189","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:00:33Z","timestamp":1761552033000},"page":"8597-8603","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review"],"prefix":"10.1097","volume":"87","author":[{"given":"Abdulrahman","family":"Saad Alfaiz","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Shaqra College of Medicine, Shaqra University, Shaqra city, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"R2-20260319","doi-asserted-by":"crossref","first-page":"2038\u201349","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-20260319","doi-asserted-by":"crossref","first-page":"e020961","DOI":"10.1136\/bmjopen-2017-020961","article-title":"Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016-2017","volume":"8","author":"Basit","year":"2018","journal-title":"BMJ Open"},{"key":"R5-20260319","doi-asserted-by":"crossref","first-page":"153\u201365","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"R6-20260319","doi-asserted-by":"crossref","first-page":"75\u201386","DOI":"10.1016\/j.peptides.2013.01.014","article-title":"Glucagon-like peptides 1 and 2 in health and disease: a review","volume":"44","author":"Marathe","year":"2013","journal-title":"Peptides"},{"key":"R7-20260319","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"R8-20260319","doi-asserted-by":"crossref","first-page":"971\u201384","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"R9-20260319","first-page":"100082","article-title":"Transparency in the reporting of artificial intelligence\u2013the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R10-20260319","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R11-20260319","doi-asserted-by":"crossref","first-page":"17\u201325","DOI":"10.1016\/j.ajog.2024.08.024","article-title":"Glucagon-like peptide-1 receptor agonist use in pregnancy: a review","volume":"232","author":"Drummond","year":"2025","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20260319","doi-asserted-by":"crossref","first-page":"e70021","DOI":"10.1111\/bcpt.70021","article-title":"Pregnancy outcomes after semaglutide exposure","volume":"136","author":"Kolding","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R13-20260319","first-page":"CD013505","article-title":"Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome","volume":"12","author":"Sharpe","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20260319","doi-asserted-by":"crossref","first-page":"521\u201339","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endoc Metab Disord"},{"key":"R15-20260319","doi-asserted-by":"crossref","first-page":"1241\u201347","DOI":"10.1007\/s00404-024-07849-9","article-title":"Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review","volume":"311","author":"Price","year":"2025","journal-title":"Arch Gynecol Obstet"},{"key":"R16-20260319","doi-asserted-by":"crossref","first-page":"31\u201347","DOI":"10.1111\/dom.16422","article-title":"Metformin use in women with polycystic ovary syndrome (PCOS): opportunities, benefits, and clinical challenges","volume":"27","author":"Saadati","year":"2025","journal-title":"Diabetes Obesity Metab"},{"key":"R17-20260319","doi-asserted-by":"crossref","first-page":"1016639","DOI":"10.3389\/fphar.2022.1016639","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R18-20260319","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/nu11030492","article-title":"Predictors of lifestyle intervention attrition or weight loss success in women with polycystic ovary syndrome who are overweight or obese","volume":"11","author":"Moran","year":"2019","journal-title":"Nutrients"},{"key":"R19-20260319","first-page":"498","article-title":"Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes","volume":"35","author":"Jackson","year":"2010","journal-title":"Pharm Ther"},{"key":"R20-20260319","doi-asserted-by":"crossref","first-page":"2555\u201370","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: a systematic review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R21-20260319","article-title":"Dual benefits and risks: tirzepatide\u2019s impact on pancreatic function","volume":"22","author":"\u0218olea","year":"2025","journal-title":"Intern Med\/Medicina Interna"},{"key":"R22-20260319","doi-asserted-by":"crossref","first-page":"2555\u201370","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical Pharmacokinetics of Semaglutide: a Systematic Review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"R25-20260319","doi-asserted-by":"crossref","first-page":"1606\u201316","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"R26-20260319","doi-asserted-by":"crossref","first-page":"587\u201397","DOI":"10.1080\/14656566.2023.2192865","article-title":"GLP-1\/GIP analogs: potential impact in the landscape of obesity pharmacotherapy","volume":"24","author":"Lafferty","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"R29-20260319","first-page":"Cd013505","article-title":"Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome","volume":"12","author":"Sharpe","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R30-20260319","doi-asserted-by":"crossref","first-page":"106984","DOI":"10.1016\/j.ntt.2021.106984","article-title":"Long-term functional alterations following prenatal GLP-1R activation","volume":"87","author":"Graham","year":"2021","journal-title":"Neurotoxicol Teratol"},{"key":"R31-20260319","doi-asserted-by":"crossref","first-page":"835\u201343","DOI":"10.2147\/DMSO.S184767","article-title":"Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis","volume":"11","author":"Seko","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R32-20260319","doi-asserted-by":"crossref","first-page":"1753495X251346330","DOI":"10.1177\/1753495X251346330","article-title":"Pregnancy outcomes following first trimester exposure to semaglutide","author":"Morton","year":"2025","journal-title":"Obstet Med"},{"key":"R33-20260319","doi-asserted-by":"crossref","first-page":"2682\u201383","DOI":"10.1111\/apa.17412","article-title":"Exposure to GLP-1 receptor agonists in early pregnancy did not increase the risk of congenital malformations","volume":"113","author":"Kuitunen","year":"2024","journal-title":"Acta Paediatr"},{"key":"R34-20260319","doi-asserted-by":"crossref","first-page":"418\u201319","DOI":"10.1111\/j.1742-1241.2000.tb10890.x","article-title":"Pregnancy outcome in women with type 2 diabetes mellitus needs to be addressed","volume":"54","author":"Brydon","year":"2000","journal-title":"Int J Clin Pract"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:01:25Z","timestamp":1773936085000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004189","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"2025-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}